<DOC>
	<DOCNO>NCT00733616</DOCNO>
	<brief_summary>The purpose study determine efficacy safety combination therapy adjusted-dose docetaxel-oxaliplatin-capecitabine patient advance gastric adenocarcinoma intermediate general status . ( defined ECOG 2 weight loss 10-25 % old 70 year comorbidities functional dependency geriatric syndrome )</brief_summary>
	<brief_title>Efficacy Safety Study Combination Therapy With Docetaxel-oxaliplatin-capecitabine Patients With Advanced Gastric Adenocarcinoma Intermediate General Status</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1. informed consent sign 2 . Histological cytological adenocarcinoma confirmation carcinoma esophagogastric union stomach ( type I , II III Siervent ) metastatic relapse 3. measurable disease ( follow RECIST criterion ) 4. old equal 70 year old 5 . Intermediate general status define least one follow characteristic : performance status ( ECOG ) = 2 , weight loss ponderada 10 25 % last 3 month 6. life expectancy superior 12 week 7. adequate hematological function : Neutrophils ≥1.50x109 , platelets ≥100x109 , Hemoglobin ≥10 g/dl 8. adequate liver function : Liver function ( total bilirubine &lt; 2 NV ; GOT GPT &lt; 3 NV ( &lt; 5 NV case liver metastasis ; Alkaline phosphatase &lt; 3 NV ) ) 9 . Adequate renal function : renal function ( Creatinine clearance &gt; 50mL/min ) , base Cockroff Gault . In case Creatinine clearance &lt; 50 ml/min , test urine do 24 hour value &gt; 50 ml/min , patient could eligible study 10 . Potential fertile woman negative pregnancy test serum urine , 10 day prior first study dose give 11 . Use adequate contraceptive method ( postmenopausal woman amenorrheic least 12 month previous study consider potentially fertile ( VN : upper limit normal laboratory value ) 1. non measurable lesion disease evidence 2. previous chemotherapy treatment advance disease . It wont´t consider exclusion criterion chemo radiotherapy give localized disease finish 1 year ago . In caso o measurable disease radiate area , progressive disease document previous inclusion 3. functional dependency 4. hypersensitivity Docetaxel , oxaliplatin capecitabine 5. previous serious adverse event unexpected fluoropirimidin treatment /or patient prove deficit dehidropirimidin deshidrogenase ( DPD ) 6. patient classify `` weak fragile '' 1. dependency one daily activity follow daily activity scale Katz 2. three comorbitities follow : congestive cardiac insufficiency , cardiac valvulopathy , coronaripathia , chronic pulmonary disease ( obstructive restrictive ) , cerebrovascular disease , diabetes , concomitant neoplasm , collagen vascular disease , chronic hetopathy incapacitate arthritis 3. presence geriatric syndrome : moderatesevere dementia , stress delirium ( urinary respiratory infection ) ; moderatesevere depression interfere habitual daily life ; frequent fall ( 3 monthly ) ; disattended ; urinary incontinence , without stress , infection , diuretic prostatic hyperplasia ; fecal incontinence without diarrhea laxative ; osteoporotic fracture long bone vertebral squash 7 . Cardiac concomitant present : 1 . Symptomatic auriculoventricular arrhythmia history , /or 2 . Congestive cardiac insufficiency non control drug , / 3 . Myocardial infarct 12 month previous inclusion , /or 4 . Symptomatic ischemic cardiopathy 8. active infectious process ( ( leukocytes superior 12 x 109/l fever upper 38º , require thorax X : ray , hemoculture urine culture 5 day previous inclusion ) 9. severe bad control concomitant disease 10. neoplastic history ( except skin basocellular insitu cervical carcinoma properly treat ) last 5 year 11. patient medical surgical important problem , investigator opinion , could allow follow treatment 12. able fulfill protocol followup 13. involve investigational trial drug within 4 week prior study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>advanced gastric adenocarcinoma</keyword>
	<keyword>docetaxel</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>intermediate general status</keyword>
</DOC>